A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 5000 participants.
Also called NCT06742723
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 5,000 participants
- Sponsor
- Registry
-
NCT06742723 -
2023-506460-14-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Denmark, Egypt, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Peru, Philippines, Poland, Romania, Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam
- Registry status
- Recruiting
Technical summary
Registry record NCT06742723. Randomized; quadruple masking; primary purpose treatment. Start 2025-03-03 (actual); primary completion 2029-12-18 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
- Acronym
- BaxDuo-Pacific
- Condition
- Chronic Kidney Disease and Hypertension
- Intervention (Drug)
- Baxdrostat/dapagliflozin
- Intervention (Drug)
- Placebo/dapagliflozin
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct06742723- Content hash
49116b8484dd170e2f418d7105430432d4cd3d0047666f50a74268c901f3ef00